Hologic, Inc. (HOLX): Price and Financial Metrics
Hologic, Inc. (HOLX)
Today's Latest Price: $69.51 USD
Updated Nov 27 1:00pm
Add HOLX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
HOLX Stock Summary
- With a market capitalization of $17,535,770,671, Hologic Inc has a greater market value than 89.03% of US stocks.
- Hologic Inc's stock had its IPO on March 26, 1990, making it an older stock than 84.84% of US equities in our set.
- In terms of twelve month growth in earnings before interest and taxes, Hologic Inc is reporting a growth rate of -1,060.74%; that's higher than only 1.81% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Hologic Inc are GRUB, QRTEA, IVAC, REVG, and AMG.
- Visit HOLX's SEC page to see the company's official filings. To visit the company's web site, go to www.hologic.com.
HOLX Stock Price Chart Interactive Chart >
HOLX Price/Volume Stats
| Current price | $69.51 | 52-week high | $77.49 |
| Prev. close | $68.23 | 52-week low | $26.49 |
| Day low | $68.39 | Volume | 624,400 |
| Day high | $69.53 | Avg. volume | 2,501,726 |
| 50-day MA | $68.32 | Dividend yield | N/A |
| 200-day MA | $56.61 | Market Cap | 17.86B |
Hologic, Inc. (HOLX) Company Bio
Hologic Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States and internationally. The company operates in four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company was founded in 1985 and is based in Bedford, Massachusetts.
HOLX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $69.51 | $38.36 | -44% |
We started the process of determining a valid price forecast for Hologic Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Hologic Inc ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 44%. As for the metrics that stood out in our discounted cash flow analysis of Hologic Inc, consider:
- HOLX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 26.29% of tickers in our DCF set.
- Hologic Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
- The weighted average cost of capital for the company is 8. This value is greater than just 20.97% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -45% |
| 1% | -45% |
| 2% | -44% |
| 3% | -44% |
| 4% | -43% |
| 5% | -43% |
CMD, DYNT, MD, RSCF, and GSK can be thought of as valuation peers to HOLX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...